Trial Profile
A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Flotetuzumab (Primary)
- Indications Acute biphenotypic leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Haematological malignancies; Hairy cell leukaemia; Hodgkin's disease; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
- Focus Therapeutic Use
- 15 Dec 2020 Planned initiation date changed from 10 Apr 2020 to 20 Oct 2020.
- 15 Dec 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to RSS recommendation.
- 22 Jan 2020 Planned initiation date changed from 10 Jan 2020 to 10 Apr 2020.